5th International AIDS Society Conference on HIV Pathogenesis and Treatment Cape Town - July 19 - 22, 2009

INFORMING DECISION-MAKING ON MALE CIRCUMCISION FOR HIV PREVENTION IN HIGH HIV PREVALENCE SETTINGS: INSIGHTS FROM MODELLING

IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: Abstract No. MOPDC106

C. Hankins ¹, N. Lohse¹, T. Hallett², N. Nagelkerke³, R. White⁴, L. Abu-Raddad⁵, H. Weiss⁴, R. Gray⁶, J. Stover⁷, UNAIDS/WHO/SACEMA Expert Group on Modelling the Impact and Cost of Male Circumcision for HIV Prevention
¹UNAIDS, Evidence, Monitoring and Policy, Geneva, Switzerland, ²Imperial College, London, United Kingdom, ³United Arab Emirates University, Al Ain, United Arab Emirates, ⁴London School of Hygiene and Tropical Medicine (University of London), London, United Kingdom, ⁵Weill Cornell Medical College, Doha, Qatar, ⁶John Hopkins Bloomberg School of Public Health, Baltimore, United States, ⁷Futures Institute, Glastonbury, United States

BACKGROUND: Decision-makers in high HIV prevalence/low male circumcision countries have asked whether introduction or expansion of male circumcion services is likely to be cost-effective for the reduction of HIV incidence over the short-, medium- and long-term. Mathematical models addressing costing and impact questions have helped refine a Decision-Makers' Programme Planning Tool.

METHODS: Modellers, epidemiologists, economists, statisticians, policy makers, and male circumcision trial investigators compared assumptions, methodologies, and results of simulation models and costing studies of male circumcision for HIV prevention. Outcomes included cost per HIV infection averted, potential for cost savings, impact on women, effects of risk compensation, influence of early post-operative sex, and potential synergies with other HIV prevention programming.

RESULTS: Not all models addressed all questions but consensus emerged with comparable findings on population-level impact of male circumcision on HIV incidence, despite different methods, baseline assumptions, and input variables. In high HIV prevalence/ low male circumcision populations, one HIV infection is averted for every 5 to 15 circumcisions performed; the cost to avert one HIV infection is $150 to $900, using a 10 year time horizon. Women benefit indirectly from reduced HIV prevalence in male partners. Potentially increased transmission or acquisition due to early post-operative resumption of sex has small population-level effects over 10-20 years. Behavioural risk compensation confined to newly or already-circumcised heterosexual men and their partners has minor effects on projected population-level benefits. Insights from this comparative analysis of models helped refine the Decision-Makers´ Programme Planning Tool subsequently used in Namibia and Botswana for programme planning.

CONCLUSIONS: Using mathematical modelling to refine and validate a user-friendly tool that can be deployed locally allows decision-makers to indirectly access main modelling findings to estimate HIV incidence, AIDS deaths, overall costs, and net cost per infection averted as a function of procedures performed, service delivery mode, and rate of scale-up.

Download PDF of this abstract.

2009-07-22
MOPDC106
Male Circumcision - Ongoing Research

Copyright © 2009 - International AIDS Society (IAS). All information and content relating to the abstracts from the 5th International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.